Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of P1101 prefilled syringe versus pen in healthy Japanese adults
jRCT2051260195Recruiting
- Sponsor
- PharmaEssentia
- Start
- Oct 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of ropeginterferon alfa-2b (2 arms), sponsored by PharmaEssentia. Primary endpoint: Bioequivalence. Started Oct 2026; status: recruiting.
02
Drugs
ropeginterferon alfa-2b
Beyond the preview
Go deeper on jRCT2051260195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051260195.